These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23436419)

  • 21. High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.
    Nanni P; Nicoletti G; Landuzzi L; Croci S; Murgo A; Palladini A; Antognoli A; Ianzano ML; Stivani V; Grosso V; Maira SM; García-Echeverría C; Scotlandi K; De Giovanni C; Lollini PL
    Eur J Cancer; 2010 Feb; 46(3):659-68. PubMed ID: 20031388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer.
    Maeda H; Hori S; Nishitoh H; Ichijo H; Ogawa O; Kakehi Y; Kakizuka A
    Cancer Res; 2001 Jul; 61(14):5432-40. PubMed ID: 11454688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Target validation in mice by constitutive and conditional RNAi.
    Kleinhammer A; Wurst W; Kühn R
    Methods Mol Biol; 2013; 986():307-23. PubMed ID: 23436420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery.
    Prestwich GD
    Acc Chem Res; 2008 Jan; 41(1):139-48. PubMed ID: 17655274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.
    Yoo JY; Kim JH; Kim J; Huang JH; Zhang SN; Kang YA; Kim H; Yun CO
    Gene Ther; 2008 May; 15(9):635-51. PubMed ID: 18273054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil.
    Chu L; Gu J; Sun L; Qian Q; Qian C; Liu X
    Gene Ther; 2008 Apr; 15(7):484-94. PubMed ID: 18239605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.
    Dalton W; Anderson KC
    Clin Cancer Res; 2006 Nov; 12(22):6603-10. PubMed ID: 17121878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.
    LaCasse EC; Cherton-Horvat GG; Hewitt KE; Jerome LJ; Morris SJ; Kandimalla ER; Yu D; Wang H; Wang W; Zhang R; Agrawal S; Gillard JW; Durkin JP
    Clin Cancer Res; 2006 Sep; 12(17):5231-41. PubMed ID: 16951243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.
    Weng JR; Tsai CH; Kulp SK; Wang D; Lin CH; Yang HC; Ma Y; Sargeant A; Chiu CF; Tsai MH; Chen CS
    Cancer Res; 2007 Aug; 67(16):7815-24. PubMed ID: 17699787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
    Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
    Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
    Kelland LR
    Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
    Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
    Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New models for cancer research: human cancer stem cell xenografts.
    Baiocchi M; Biffoni M; Ricci-Vitiani L; Pilozzi E; De Maria R
    Curr Opin Pharmacol; 2010 Aug; 10(4):380-4. PubMed ID: 20561817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice.
    Yang Z; Cai JH; Xie SJ; Li GX; Song WQ; Yan QH; Yan L; Zhang F
    Chin Med J (Engl); 2011 Jun; 124(12):1854-61. PubMed ID: 21740845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
    Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective.
    Singh M; Johnson L
    Clin Cancer Res; 2006 Sep; 12(18):5312-28. PubMed ID: 17000664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.